Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FOUNTAIN INN, S.C., Aug. 27, 2018 (GLOBE NEWSWIRE) -- AVX Corporation, a leading manufacturer and supplier of advanced electronic components and interconnect, sensor, control, and antenna solutions,...
-
HENDERSON, Nev., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Blue Eagle Lithium Inc. (OTCQB:BEAG) ("Blue Eagle" or the "Company") is pleased to announce the official launch of the Company's new corporate...
-
DURHAM, N.C., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Prescient, a fully integrated BIM design and building platform that dramatically reduces the time and cost of constructing multi-unit housing, today...
-
Lundin Petroleum AB (Lundin Petroleum) meddelar positiva uppdateringar för Johan Sverdrupprojektet samt att utbyggnadsplanen för andra fasen lämnas in. En sammanställning av uppdateringarna som...
-
Lundin Petroleum AB (Lundin Petroleum) is pleased to announce an update on the Johan Sverdrup development project in relation to a number of key metric improvements and submission of the Phase 2 plan...
-
Highlights Golar LNG Limited ("Golar" or "the Company") reports net income of $36.3 million for the second quarter of 2018 ("2Q"). EBITDA1 for the quarter was $98.9 million, including $94.7...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} EBITDA for the second quarter amounted...
-
Albany, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) -- The global automotive lubricants market depicts the presence of a highly fragmented and competitive vendor landscape, says Transparency Market...
-
ENGLEWOOD CLIFFS, N.J., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for...
-
Opened three clinical trials in 2018Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which...